MaaT Pharma Reports Results from the P-Ib (IASO) Study of MaaT033 for Treating Amyotrophic Lateral Sclerosis (ALS)
Shots:
- MaaT Pharma has reported results from preliminary microbiome analysis of P-IB (IASO) trial assessing MaaT033 for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS)
- Trial showed that MaaT033 achieved its 1EPs of safety and tolerability in ALS patients over 2 months, as confirmed by DSMB. Microbiome analysis verifies successful engraftment of MaaT033, supporting its safety and tolerability.
- Additional endpoints will be analysed in the coming months; the DSMB recommends advancing MaaT033 to P-II in early 2025, for which next steps will be decided based on P-Ib data, possibly including a larger efficacy study. Key data will be highlighted at the ALS/MND symposium 2024
Ref: MaaT Pharma | Image: MaaT Pharma
Related News:- The US FDA Lifts Clinical Hold for MaaT Pharma’s MaaT013 to Treat Acute Graft-versus-Host Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
